Actos Bladder Cancer Lawsuit
Actos class action lawsuit filed in Canada

A class action lawsuit has been filed on behalf of consumers who have developed bladder cancer after taking the popular diabetes medication, Actos, manufactured by Japan’s largest drug maker Takeda Pharmaceuticals.

The complaint was filed on December 21st in the Ontario Superior Court of Justice by the estate of a Toronto woman who died in 2011 from bladder cancer believed to be caused by Actos.

Actos (pioglitazone) was first introduced in July of 1999 and was designed to aid the body’s sensitivity to insulin in patients that have been diagnosed with type II diabetes. Since its release, Actos became Takeda Pharmaceuticals best-selling drug with record sales of $4.3 billion in 2010, marking it as one of the top-ten best-selling drugs in the United States.

French drug regulators forced a recall of the Actos medication in that same year, contributing the recall to an increasing number of bladder cancer cases caused by Actos. In September of 2010 the Food and Drug Administration (FDA) began reviewing Actos risks and later required that Actos have updated warning labels.

Increased concerns regarding the link between Actos and bladder cancer have increased. As a result, a number of lawsuits have been filed along with necessary regulation by the Food and Drug Administration to protect consumers who use the medication.

So far, dozens of Actos bladder cancer cases have been filed in various federal district courts. Similar claims, that taking the type II diabetes drug has caused bladder cancer, have been made amongst all of these cases.

According to the complaint filed in Canada, Takeda Pharmaceuticals failed to properly warn doctors and patients of the risks associated with the use of Actos. The plaintiffs believe that the company knew or should have known about the risks, and are filing a lawsuit against the company as a result.


About the Contributor

Related Posts